Albumin News and Research

RSS

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

27 May 2014

Novozymes Biopharma, ThioLogics to collaborate on drug-albumin conjugation platform

Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.

14 May 2014

5-year survival of diabetic kidney transplant patients now on par with nondiabetic recipients

Mayo Clinic researchers have discovered that the five-year survival of diabetic kidney transplant patients is now on par with the five-year survival of nondiabetic kidney recipients.

9 May 2014

Perfusion system at room temperature preserves and improves metabolic function of donor livers

A system developed by investigators at the Massachusetts General Hospital (MGH) Center for Engineering in Medicine (CEM) and the MGH Transplant Center has the potential to increase both the supply and the quality of donor organs for liver transplantation.

7 May 2014

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals, Inc. today announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. CTP-499, when used in addition to the standard of care, is being developed to delay the progression of these patients to end-stage renal failure, which requires dialysis or kidney transplantation.

26 Apr 2014

Drug used to treat hypertension prevents post-traumatic epilepsy in rodent model

Between 10 and 20 percent of all cases of epilepsy result from severe head injury, but a new drug promises to prevent post-traumatic seizures and may forestall further brain damage caused by seizures in those who already have epilepsy.

23 Apr 2014

Research by UCI, Salk Institute points to novel therapies for minimizing stroke-induced brain damage

By discovering a new mechanism that allows blood to enter the brain immediately after a stroke, researchers at UC Irvine and the Salk Institute have opened the door to new therapies that may limit or prevent stroke-induced brain damage.

18 Apr 2014

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Baxter International Inc. today announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111. BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder.

From Baxter International Inc. 16 Apr 2014

Scientists uncover mechanism and possible treatment to reverse immune suppression in liver disease patients

The mechanism which underlies the susceptibility of liver disease patients to life-threatening infection has been uncovered by Wellcome Trust-funded medical scientists, who have also suggested a possible treatment to reverse immune suppression in these patients.

15 Apr 2014

Siemens, NKF form new alliance to improve screening for kidney disease in high-risk individuals

Siemens Healthcare and the National Kidney Foundation (NKF) announced today a new strategic alliance focusing on education, awareness and screening for kidney disease in high-risk individuals. This important collaboration will leverage the latest testing recommendations from the NKF to improve detection among the 73 million Americans at risk for kidney disease.

10 Apr 2014

Proprietary Novozymes technology used in GlaxoSmithKline’s new diabetes treatment

Novozymes Biopharma DK A/S, a subsidiary of Novozymes A/S, a world leader in bioinnovation, has announced that its albumin-based VELTIS half-life extension technology is being used by GlaxoSmithKline in the recently authorized Eperzan (albiglutide) for the treatment of type 2 diabetes in Europe.

1 Apr 2014

Bariatric surgery more effective than intensive medical therapy for managing type 2 diabetes

Gastric bypass and sleeve gastrectomy - two of the most commonly used bariatric surgeries - are more effective than intensive medical therapy alone when it comes to managing uncontrolled type 2 diabetes in overweight or obese patients after three years, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Bariatric surgery patients report better quality of life

A study by Cleveland Clinic researchers shows bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery.

31 Mar 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

Cytrx releases statement in response to two recent lawsuits

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx shareholders:

27 Mar 2014

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA.

25 Mar 2014

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.

24 Mar 2014

New scientific blood analysis predicts short-term mortality in humans

The general state of a person's metabolism can be diversely illustrated with a new scientific blood analysis. With the aid of the analysis biomarkers predicting short-term mortality have now been discovered

26 Feb 2014

Active ingredient in vinegar can effectively kill mycobacteria

The active ingredient in vinegar, acetic acid, can effectively kill mycobacteria, even highly drug-resistant Mycobacterium tuberculosis, an international team of researchers from Venezuela, France, and the US reports in mBio-, the online open-access journal of the American Society for Microbiology.

25 Feb 2014

Albumin News and Research

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

Novozymes Biopharma, ThioLogics to collaborate on drug-albumin conjugation platform

5-year survival of diabetic kidney transplant patients now on par with nondiabetic recipients

Perfusion system at room temperature preserves and improves metabolic function of donor livers

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Drug used to treat hypertension prevents post-traumatic epilepsy in rodent model

Research by UCI, Salk Institute points to novel therapies for minimizing stroke-induced brain damage

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Scientists uncover mechanism and possible treatment to reverse immune suppression in liver disease patients

Siemens, NKF form new alliance to improve screening for kidney disease in high-risk individuals

Proprietary Novozymes technology used in GlaxoSmithKline’s new diabetes treatment

Bariatric surgery more effective than intensive medical therapy for managing type 2 diabetes

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Bariatric surgery patients report better quality of life

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Cytrx releases statement in response to two recent lawsuits

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

New scientific blood analysis predicts short-term mortality in humans

Active ingredient in vinegar can effectively kill mycobacteria

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News